Table 1 Early-stage technology companies
Company | Technology | Disease area | R&D status | Market capitalization |
|---|---|---|---|---|
StemCells | Cell therapy | Diabetes, Parkinson’s | Preclinicals | $55 million |
Transition Therapeutics | Biopharma | Diabetes | Phase I | $78 million |
Alteon | Biopharma | Diabetes, Aging | Phase II, Preclinicals | $69 million |
Aradigm | Medical devices | Diabetes | Phase II, III | $134 million |
Aastrom Biosciences | Cell theraphy | Oncology, Dermatology | Phase I | $83 million |
Emisphere Technologies | Medical devices | Diabetes, Blood system | Phase I, II, III | $109 million |
NeoPharm | Biopharma | Oncology | Phase,I, II | $476 million |
ConjuChem | Biopharma | Deabetes, AIDS, CHF | Phase II | $589 million |
Spectrum Pharma | Biopharma | Oncology, Neurology | Preclinicals | $79 million |
Ergo Sciences | Biopharma | Diabetes | Technology sold | $15 million |